This review explores advancements in drug delivery methods for multi-unit pellet systems, highlighting patient adherence and regulatory compliance issues.
Disintegrating tablets incorporated into Multi-Unit Pellet Systems (MUPS) is an innovative method of delivering drugs that combines the benefits of multiple-unit formulations with the ease of a single-dose administration. This review article explores the difficulties and advancements in creating and using disintegrating tablets for multiple-unit pellet systems (MUPS). Key challenges include formulation complexities like manufacturing process limitations, stability concerns, and regulatory compliance barriers. Solutions to these issues involve creating advanced dosage forms like disintegrating TMUPS. The review examines case studies that illustrate the effective adoption and market expansion of MUPS, resulting in enhanced patient adherence and improved treatment results. In addition, the review emphasizes the advantages, formulation, and process-related challenges in developing disintegrating tablets of MUPS, i.e., conversion of MUPS to a single-unit system (SUS). Additionally, the discussion encompasses future and sustainable materials that can be adopted to advance the formulation development of disintegrating TMUPS. It emphasizes the continual efforts to overcome current obstacles and take advantage of new opportunities to improve drug delivery.
No takes yet. Share an insight, caveat, or question.
VAIDYA et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: